Analyst firms · Wells Fargo · EXAS
Wells Fargo EXAS price target and rating history
Exact Sciences Corporation (EXAS) · Health Care
Wells Fargo rates Exact Sciences Corporation (EXAS) Overweight with a $75 price target, as of its latest action on Aug 28, 2024. It has published 3 rating actions on EXAS since November 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Overweight
- Price target
- $75
- Median target, all firms
- Too few
- Actions on EXAS
- 3
Wells Fargo price target on EXAS
Every Wells Fargo rating on EXAS
- Aug 28, 2024
- Feb 23, 2022
- Nov 3, 2021
How other firms rate EXAS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Mizuho | Neutral | $105 | Jan 20, 2026 |
| Evercore ISI | In-line | $105 | Jan 5, 2026 |
Questions about Wells Fargo and EXAS
- What is Wells Fargo's price target for EXAS?
- Wells Fargo's latest stated price target for Exact Sciences Corporation (EXAS) is $75, from its action on Aug 28, 2024.
- What is Wells Fargo's rating on EXAS?
- Wells Fargo rates EXAS Overweight, a bullish rating, as of Aug 28, 2024.
- When did Wells Fargo last change its view on EXAS?
- On Aug 28, 2024, Wells Fargo starts coverage at Overweight, price target $75.
More EXAS rating histories
All Wells Fargo ratingsEXAS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.